T-Cell Lymphomas - Pipeline Review, H1 2014

  • April 2014
  • -
  • Global Markets Direct
  • -
  • 132 pages

T-Cell Lymphomas - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘T-Cell Lymphomas - Pipeline Review, H1 2014’, provides an overview of the T-Cell Lymphomas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of T-Cell Lymphomas
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for T-Cell Lymphomas and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the T-Cell Lymphomas pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

T-Cell Lymphomas - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
T-Cell Lymphomas Overview 8
Therapeutics Development 9
Pipeline Products for T-Cell Lymphomas - Overview 9
Pipeline Products for T-Cell Lymphomas - Comparative Analysis 10
T-Cell Lymphomas - Therapeutics under Development by Companies 11
T-Cell Lymphomas - Therapeutics under Investigation by Universities/Institutes 13
T-Cell Lymphomas - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Clinical Stage Products 15
Early Stage Products 16
T-Cell Lymphomas - Products under Development by Companies 17
T-Cell Lymphomas - Products under Investigation by Universities/Institutes 18
T-Cell Lymphomas - Companies Involved in Therapeutics Development 19
Bristol-Myers Squibb Company 19
Kyowa Hakko Kirin Co., Ltd. 20
Amgen Inc. 21
Seattle Genetics, Inc. 22
Infinity Pharmaceuticals, Inc. 23
Nippon Kayaku Co., Ltd. 24
Ono Pharmaceutical Co., Ltd. 25
Celgene Corporation 26
Onyx Pharmaceuticals, Inc. 27
Mundipharma International Limited 28
Pharmacyclics, Inc. 29
Cell Medica Limited 30
Pharma Mar, S.A. 31
Rhizen Pharmaceuticals SA 32
T-Cell Lymphomas - Therapeutics Assessment 33
Assessment by Monotherapy Products 33
Assessment by Target 34
Assessment by Mechanism of Action 37
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
mogamulizumab - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
brentuximab vedotin - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
mogamulizumab - Drug Profile 51
Product Description 51
Mechanism of Action 51
RandD Progress 51
forodesine hydrochloride - Drug Profile 53
Product Description 53
Mechanism of Action 53
RandD Progress 53
plitidepsin - Drug Profile 55
Product Description 55
Mechanism of Action 55
RandD Progress 55
lenalidomide - Drug Profile 57
Product Description 57
Mechanism of Action 57
RandD Progress 57
CMD-003 - Drug Profile 60
Product Description 60
Mechanism of Action 60
RandD Progress 60
carfilzomib - Drug Profile 61
Product Description 61
Mechanism of Action 61
RandD Progress 61
nivolumab - Drug Profile 64
Product Description 64
Mechanism of Action 64
RandD Progress 64
duvelisib - Drug Profile 68
Product Description 68
Mechanism of Action 68
RandD Progress 68
BMS-906024 - Drug Profile 70
Product Description 70
Mechanism of Action 70
RandD Progress 70
AMG-319 - Drug Profile 71
Product Description 71
Mechanism of Action 71
RandD Progress 71
RP-6530 - Drug Profile 72
Product Description 72
Mechanism of Action 72
RandD Progress 72
Drugs to Inhibit PDGFR-Beta Receptor for T-Cell Lymphomas - Drug Profile 73
Product Description 73
Mechanism of Action 73
RandD Progress 73
PCI-34051 - Drug Profile 74
Product Description 74
Mechanism of Action 74
RandD Progress 74
NK-314 - Drug Profile 75
Product Description 75
Mechanism of Action 75
RandD Progress 75
Drug for T-Cell Lymphoma - Drug Profile 76
Product Description 76
Mechanism of Action 76
RandD Progress 76
T-Cell Lymphomas - Recent Pipeline Updates 77
T-Cell Lymphomas - Dormant Projects 120
T-Cell Lymphomas - Discontinued Products 121
T-Cell Lymphomas - Product Development Milestones 122
Featured News and Press Releases 122
Feb 10, 2014: Change to Supplemental Application Seeking Approval of Additional Indication for Mogamulizumab 122
Feb 06, 2014: Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Beleodaqâ„¢ (belinostat) for Injection, a novel pan-HDAC inhibitor 122
Jan 23, 2014: Infinity Reports Phase 1 Data of IPI-145 at Sixth Annual T-Cell Lymphoma Forum 123
Dec 11, 2013: Spectrum Pharmaceuticals Highlights Encouraging FOLOTYN Clinical Data Presented at the 55th Annual Meeting of the American Society of Hematology 124
Dec 06, 2013: Spectrum Pharmaceuticals Highlights Abstracts On Folotyn at the 55th Annual Meeting of the American Society of Hematology 125
Dec 06, 2013: Rhizen Pharmaceuticals announces initiation of a “First in Human” Phase-1 trial of RP6530, a dual PI3K delta/gamma inhibitor, in patients with hematological malignancies 125
Dec 05, 2013: TG Therapeutics Announces Poster Presentations for TGR-1202 at the Upcoming 55th American Society of Hematology Meeting 126
Nov 19, 2013: Rhizen Pharmaceuticals announces preclinical presentations on RP6530, a dual PI3K delta/gamma inhibitor, for the treatment of hematological malignancies at the 55th Annual Meeting of the American Society of Hematology, 2013 127
Jul 19, 2013: Application Seeking Approval for Additional Indication for ATL, PTCL and CTCL of Mogamulizumab 127
Jun 24, 2013: Infinity Pharma Reports Phase I Data Showing Encouraging Clinical Activity Of IPI-145 Across Broad Range Of Blood Cancers At 12th ICML 128
Appendix 131
Methodology 131
Coverage 131
Secondary Research 131
Primary Research 131
Expert Panel Validation 131
Contact Us 132
Disclaimer 132

List of Tables

Number of Products under Development for T-Cell Lymphomas, H1 2014 9
Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 12
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Development, H1 2014 16
Products under Development by Companies, H1 2014 17
Products under Investigation by Universities/Institutes, H1 2014 18
T-Cell Lymphomas - Pipeline by Bristol-Myers Squibb Company, H1 2014 19
T-Cell Lymphomas - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 20
T-Cell Lymphomas - Pipeline by Amgen Inc., H1 2014 21
T-Cell Lymphomas - Pipeline by Seattle Genetics, Inc., H1 2014 22
T-Cell Lymphomas - Pipeline by Infinity Pharmaceuticals, Inc., H1 2014 23
T-Cell Lymphomas - Pipeline by Nippon Kayaku Co., Ltd., H1 2014 24
T-Cell Lymphomas - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2014 25
T-Cell Lymphomas - Pipeline by Celgene Corporation, H1 2014 26
T-Cell Lymphomas - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 27
T-Cell Lymphomas - Pipeline by Mundipharma International Limited, H1 2014 28
T-Cell Lymphomas - Pipeline by Pharmacyclics, Inc., H1 2014 29
T-Cell Lymphomas - Pipeline by Cell Medica Limited, H1 2014 30
T-Cell Lymphomas - Pipeline by Pharma Mar, S.A., H1 2014 31
T-Cell Lymphomas - Pipeline by Rhizen Pharmaceuticals SA, H1 2014 32
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Stage and Target, H1 2014 36
Number of Products by Stage and Mechanism of Action, H1 2014 39
Number of Products by Stage and Route of Administration, H1 2014 41
Number of Products by Stage and Molecule Type, H1 2014 43
T-Cell Lymphomas Therapeutics - Recent Pipeline Updates, H1 2014 77
T-Cell Lymphomas - Dormant Projects, H1 2014 120
T-Cell Lymphomas - Discontinued Products, H1 2014 121

List of Figures

Number of Products under Development for T-Cell Lymphomas, H1 2014 9
Number of Products under Development for T-Cell Lymphomas - Comparative Analysis, H1 2014 10
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 13
Comparative Analysis by Late Stage Development, H1 2014 14
Comparative Analysis by Clinical Stage Development, H1 2014 15
Comparative Analysis by Early Stage Products, H1 2014 16
Assessment by Monotherapy Products, H1 2014 33
Number of Products by Top 10 Target, H1 2014 34
Number of Products by Stage and Top 10 Target, H1 2014 35
Number of Products by Top 10 Mechanism of Action, H1 2014 37
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 38
Number of Products by Top 10 Route of Administration, H1 2014 40
Number of Products by Stage and Top 10 Route of Administration, H1 2014 41
Number of Products by Top 10 Molecule Type, H1 2014 42
Number of Products by Stage and Top 10 Molecule Type, H1 2014 43

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • December 2014
  • by GBI Research

Frontier Pharma: Liver Cancer - Identifying and Commercializing First-in-Class Innovation Summary Large and Diverse Pipeline The liver cancer pipeline contains 238 products in active development, approximately ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • January 2015
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...

Therapeutics for ”Silent” Cancers

Therapeutics for ”Silent” Cancers

  • $ 6 650
  • Industry report
  • February 2015
  • by BCC Research

REPORT HIGHLIGHTS The global market for “silent” cancers was valued at $8.5 billion in 2013 and $9 billion in 2014. This market is expected to reach almost $13.6 billion by 2019, with a compound annual ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.